Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$6.28 -5.8%	$6.08	$3.56 ▼ $12.92	$376.42M	0.48	213,425 shs	177,444 shs
CURR Currenc Group	$1.52 -6.7%	$1.20	$0.33 ▼ $12.89	$75.84M	-0.13	646,859 shs	232,844 shs
CYDY CytoDyn	$0.26 -1.7%	$0.31	$0.10 ▼ $0.49	$328.53M	1.23	1.17 million shs	1.32 million shs
FULC Fulcrum Therapeutics	$6.49 -4.7%	$7.18	$2.32 ▼ $10.13	$368.36M	2.47	998,450 shs	411,910 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	-5.85%	-4.27%	-7.24%	+48.46%	-34.92%
CURR Currenc Group	-6.75%	-23.62%	-25.12%	+27.73%	+151,999,900.00%
CYDY CytoDyn	-1.72%	-12.00%	-17.63%	-35.46%	+96.41%
FULC Fulcrum Therapeutics	-4.70%	-4.98%	-17.95%	+20.86%	-21.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATXS Astria Therapeutics	2.154 of 5 stars	3.6	2.0	2.5	1.7	0.0
CURR Currenc Group	1.8619 of 5 stars	3.8	0.0	1.5	1.7	0.0
CYDY CytoDyn	0.1939 of 5 stars	0.0	1.0	1.1	0.0	1.3
FULC Fulcrum Therapeutics	2.4241 of 5 stars	3.3	3.0	2.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	3.29	Buy	$29.00	361.78% Upside
CURR Currenc Group	3.50	Strong Buy	$3.50	130.26% Upside
CYDY CytoDyn	0.00	N/A	N/A	N/A
FULC Fulcrum Therapeutics	2.63	Moderate Buy	$7.57	16.66% Upside

Current Analyst Ratings Breakdown

Latest CURR, ATXS, FULC, and CYDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	FULC Fulcrum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $5.00
7/29/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$4.00 ➝ $12.00
6/13/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.97 per share	N/A
CURR Currenc Group	$46.44M	1.52	N/A	N/A	($0.71) per share	-2.14
CYDY CytoDyn	N/A	N/A	$0.00 per share	78.63	($0.08) per share	N/A
FULC Fulcrum Therapeutics	$80M	4.39	N/A	N/A	$3.96 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$1.87	N/A	N/A	N/A	N/A	-47.18%	-31.26%	8/11/2025 (Estimated)
CURR Currenc Group	-$39.47M	-$1.06	N/A	∞	N/A	-102.10%	N/A	-39.14%	8/19/2025 (Estimated)
CYDY CytoDyn	$3.74M	$0.01	25.78	∞	N/A	N/A	N/A	-4.40%	8/13/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$1.22	N/A	N/A	N/A	N/A	-31.05%	-28.96%	N/A

Latest CURR, ATXS, FULC, and CYDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	Q2 2025	CURR Currenc Group	-$0.04	N/A	N/A	N/A	$10.40 million	N/A
8/11/2025	Q2 2025	ATXS Astria Therapeutics	-$0.61	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	CURR Currenc Group	-$0.04	-$0.10	-$0.06	-$0.10	$10.40 million	$8.71 million
7/29/2025	Q2 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
7/25/2025	Q4 2025	CYDY CytoDyn	N/A	-$0.01	N/A	-$0.01	N/A	N/A
5/20/2025	Q1 2025	CURR Currenc Group	-$0.04	-$0.13	-$0.09	-$0.13	$10.50 million	$10.06 million
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
CURR Currenc Group	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	17.39	17.39
CURR Currenc Group	N/A	0.62	0.61
CYDY CytoDyn	N/A	0.25	0.25
FULC Fulcrum Therapeutics	N/A	24.42	24.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
CURR Currenc Group	56.01%
CYDY CytoDyn	5.06%
FULC Fulcrum Therapeutics	89.83%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
CURR Currenc Group	17.80%
CYDY CytoDyn	0.54%
FULC Fulcrum Therapeutics	7.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	56.43 million	53.89 million	Optionable
CURR Currenc Group	2	46.53 million	38.25 million	N/A
CYDY CytoDyn	20	1.25 billion	1.25 billion	Not Optionable
FULC Fulcrum Therapeutics	100	54.09 million	50.31 million	Optionable

CURR, ATXS, FULC, and CYDY Headlines

Recent News About These Companies

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 8 at 4:30 PM | globenewswire.com

AIRNA Appoints Tamara Joseph as Chief Legal Officer and Kristina Storey as Head of Regulatory Affairs

August 6 at 7:00 PM | finance.yahoo.com

FULC Fulcrum Therapeutics, Inc. - Seeking Alpha

August 5, 2025 | seekingalpha.com

FY2025 EPS Estimates for FULC Increased by Cantor Fitzgerald

August 3, 2025 | americanbankingnews.com

HC Wainwright Issues Positive Outlook for FULC Earnings

August 3, 2025 | americanbankingnews.com

FY2025 EPS Estimates for FULC Raised by Cantor Fitzgerald

August 2, 2025 | marketbeat.com

HC Wainwright Issues Optimistic Outlook for FULC Earnings

August 2, 2025 | marketbeat.com

Leerink Partnrs Has Negative Forecast for FULC Q3 Earnings

August 2, 2025 | marketbeat.com

Brokerages Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Target Price at $6.29

August 2, 2025 | americanbankingnews.com

Q3 EPS Estimate for Fulcrum Therapeutics Reduced by Analyst

August 2, 2025 | americanbankingnews.com

Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

July 31, 2025 | marketbeat.com

Fulcrum Therapeutics upgraded to Buy from Neutral at H.C. Wainwright

July 30, 2025 | msn.com

Fulcrum Therapeutics (NASDAQ:FULC) Upgraded at HC Wainwright

July 30, 2025 | marketbeat.com

Fulcrum Therapeutics (NASDAQ:FULC) Raised to Buy at HC Wainwright

July 30, 2025 | americanbankingnews.com

Fulcrum Therapeutics shares slide 17% after sickle cell trial results

July 29, 2025 | msn.com

Fulcrum reports data from sickle cell disease trial, posts Q2 results

July 29, 2025 | msn.com

Fulcrum Therapeutics stock falls after sickle cell disease trial results

July 29, 2025 | investing.com

Fulcrum study results suggest a pill can treat sickle cell disease

July 29, 2025 | statnews.comS

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

July 29, 2025 | globenewswire.com

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

July 29, 2025 | globenewswire.com

Fulcrum Therapeutics stock soars ahead of sickle cell trial data

July 29, 2025 | za.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bitcoin and Dividends: A Winning Combo in These 3 ETFs
By Nathan Reiff | August 2, 2025
View Bitcoin and Dividends: A Winning Combo in These 3 ETFs
Qualcomm: Undervalued Chip Stock in Breakout Uptrend
By Sam Quirke | July 17, 2025
View Qualcomm: Undervalued Chip Stock in Breakout Uptrend
Cameco's 80% 3-Month Gain May Be Just the Start
By Jeffrey Neal Johnson | July 17, 2025
View Cameco's 80% 3-Month Gain May Be Just the Start
Crypto Skeptics Can Still Win Big With These Risk-Limiting ETFs
By Nathan Reiff | July 26, 2025
View Crypto Skeptics Can Still Win Big With These Risk-Limiting ETFs
Homebuilding Headwinds Putting These 3 Stocks Under Pressure
By Dan Schmidt | July 27, 2025
View Homebuilding Headwinds Putting These 3 Stocks Under Pressure

CURR, ATXS, FULC, and CYDY Company Descriptions

Astria Therapeutics NASDAQ:ATXS

$6.28 -0.39 (-5.85%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.28 0.00 (-0.08%)

As of 08/8/2025 04:10 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Currenc Group NASDAQ:CURR

$1.52 -0.11 (-6.75%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.03 (-2.30%)

As of 08/8/2025 07:51 PM Eastern

Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.

CytoDyn OTCMKTS:CYDY

$0.26 0.00 (-1.72%)

As of 08/8/2025 03:59 PM Eastern

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

Fulcrum Therapeutics NASDAQ:FULC

$6.49 -0.32 (-4.70%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.49 0.00 (0.00%)

As of 08/8/2025 07:32 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time